Your browser doesn't support javascript.
loading
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Hovingh, G Kees; Lepor, Norman E; Kallend, David; Stoekenbroek, Robert M; Wijngaard, Peter L J; Raal, Frederick J.
Afiliação
  • Hovingh GK; Department of Internal Medicine, Amsterdam UMC, The Netherlands (G.K.H.).
  • Lepor NE; Geffen School of Medicine, University of California, Los Angeles (N.E.L.).
  • Kallend D; Cardiovascular, The Medicines Company, Parsippany, NJ (D.K., R.M.S., P.L.J.W.).
  • Stoekenbroek RM; Cardiovascular, The Medicines Company, Parsippany, NJ (D.K., R.M.S., P.L.J.W.).
  • Wijngaard PLJ; Cardiovascular, The Medicines Company, Parsippany, NJ (D.K., R.M.S., P.L.J.W.).
  • Raal FJ; Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.).
Circulation ; 141(22): 1829-1831, 2020 06 02.
Article em En | MEDLINE | ID: mdl-32479195
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / RNA Interferente Pequeno / Interferência de RNA / Terapia de Alvo Molecular / Inibidores de PCSK9 / Hiperlipoproteinemia Tipo II / LDL-Colesterol Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / RNA Interferente Pequeno / Interferência de RNA / Terapia de Alvo Molecular / Inibidores de PCSK9 / Hiperlipoproteinemia Tipo II / LDL-Colesterol Idioma: En Ano de publicação: 2020 Tipo de documento: Article